About DULAGLUTID E 0.75MG/0.5M
GLP-1 receptor agonist
Used for
- Improves blood sugar control in adults with type 2 diabetes.
- Reduces cardiovascular risk in some adults with type 2 diabetes and established cardiovascular disease or risk factors.
Usual adult dose
Usually injected under the skin once weekly; the dose may be increased gradually if needed.
Usual dose in children
For children aged 10 years and older with type 2 diabetes: usually injected under the skin once weekly; dose adjustments are clinician-directed.
Common side effects
- Nausea, diarrhea, vomiting, or abdominal pain
- Reduced appetite
- Injection-site reactions
- Low blood sugar, especially with insulin or sulfonylureas
Important warnings
- Not for type 1 diabetes or treatment of diabetic ketoacidosis.
- Avoid with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
- Pancreatitis and serious allergic reactions have been reported.
- May worsen severe stomach-emptying problems; dehydration from vomiting or diarrhea can affect kidney function.
Pregnancy
May harm the fetus; generally discontinued when pregnancy is recognized. Limited human pregnancy data are available.
Breastfeeding
Human data are limited; discuss potential risks and benefits with a healthcare professional.
Interactions
- Insulin or sulfonylureas can increase low blood sugar risk.
- Slowed stomach emptying may affect absorption of oral medicines.
- May affect medicines requiring reliable or rapid absorption, including oral contraceptives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.